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Disease, 9th Revision, Clinical Modification (ICD-9-CM) code 493.xx. The first asthma 
diagnosis date was designated as the index date. Patients were required to have 12 
months continuous enrollment pre- and post-index date. Comorbid conditions were 
examined for the baseline period. Study outcomes including treatment patterns 
within 60 days after the index date, health care utilization and costs in the Medicare 
research identifiable file during the follow-up period were measured. Results: A 
total of 63,012 patients were identified for study, of which the majority was White 
(84.7%), male (68.2%) and resided in the Southern U.S. region (38.3%). The mean 
age of patients was 76 years. The Charlson Comorbidity Index score was 2.39, and 
common comorbidities included chronic obstructive pulmonary disease (42.9%), 
diabetes (33.2%) and tumor (30.2%). Patients were more often prescribed albuterol 
sulfate (19.1%), hydrocodone bitartrate/acetaminophen (14.4%) and furosemide 
(13.1%). Health care utilizations included Medicare carrier use (99.0%), Durable 
Medical Equipment (DME, 51.7%), Home Health Agency (HHA, 22.3%), outpatient 
visits (81.6%) and inpatient (40.8%), Skilled Nursing Facility (SNF, 12.6%) and hos-
pice admissions (5.0%) and prescription drug (part D event) claims (57.3%). Patient 
expenditures were calculated at $5,431 for Carrier, $726 for DME, $1,401 for HHA, 
$15,211 for outpatient, $9,162 for inpatient, $2,354 for SNF, $464 for hospice, $2,192 
for pharmacy and $36,941 for total costs. ConClusions: U.S. Medicare patients 
diagnosed with asthma were more often prescribed albuterol sulfate, experienced 
a high percentage of Medicare carrier service use and outpatient visits, as well as 
frequent comorbidities, which translated into high total health care expenses as 
evidenced by this study.
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objeCtives: Global clinical guidelines recommend fixed-dose combinations 
(FDCs) of inhaled corticosteroids (ICS) and long-acting beta agonists (LABA), 
delivered via an inhaler, as a treatment for moderate to severe persistent asthma 
and chronic obstructive pulmonary disease (COPD).  Poor inhalation technique—
measured as the occurrence of critical inhaler errors—is common with existing 
inhalers, and may contribute to the economic burden of disease management by 
increasing health care resource use. We have developed an economic model to 
evaluate the clinical and economic burden of asthma and COPD in the UK, and 
assess the impact of poor inhalation technique with ICS + LABA FDCs on costs 
and resource use. Methods: The eligible adult patient population was based on 
current confirmed asthma and COPD diagnosis rates in the UK, with the propor-
tion of patients receiving FDCs based on available market research data.  Costs 
of inhalers, scheduled care and unscheduled health care events were taken from 
publicly available sources in the UK.  Frequency of poor inhalation technique—
measured through the occurrence of critical inhaler errors—and the associated 
increased risk of unscheduled health care events were taken from a large (n = 1,664) 
cross-sectional, observational study in Italy. Results: The model estimated that 
1.3 million adults with persistent asthma and COPD receive an ICS + LABA FDC 
in the UK, annually; of which, 366,000 demonstrate poor inhalation technique. 
Total direct costs were estimated to be £875 million, with costs of unscheduled 
health care events accounting for £137 million.  Poor inhalation technique with 
ICS + LABA FDCs was estimated to be responsible for 11.8% of unscheduled health 
care costs, equating to £16.2 million annually. ConClusions: The clinical and 
economic burden associated with poor inhalation technique in asthma and COPD 
is considerable in the UK.  Novel inhalers, which improve inhalation technique, 
may offer clinical and economic benefits in the management of asthma and COPD.
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ies involving symptomatic patients defined as modified Medical Research Council 
(mMRC) score ≥ 2 or COPD assessment test (CAT) score ≥ 10 or presenting common 
symptoms of COPD were included. Studies focussed on cost of illness and resource 
use in adult symptomatic COPD patients were included. Studies meeting the eli-
gibility criteria were appraised using Drummond checklist. Results: Database 
searches yielded 4491 references which resulted in 74 relevant studies after two 
levels of screening. All the included studies were of adequate reporting quality 
with study objective and competing alternatives being defined clearly. The annual 
direct per patient costs of COPD ranged from US$522 in France to US$4119 in the 
United States. Physician consultations were the most frequently utilised resource, 
followed by ER visits and hospitalisations. The composition of direct costs differed 
between countries, with more than 50% of the direct costs resulting due to inpatient 
admissions in Canada, Italy, Spain, the UK, and the United States and almost 50% 
due to regular prescribed medicines in The Netherlands. The mean annual societal 
costs ranged from US$1023 in The Netherlands to US$5646 in the United States. The 
annual societal costs per patient were higher in patients with severe COPD, higher 
levels of dyspnoea and symptoms, frequent exacerbations, comorbid conditions, low 
educational status and former smokers. Economic burden of lost productivity was 
the highest in the US and the lowest in Italy. Lost productivity accounted for 67% of 
the total cost of COPD in France. ConClusions: The management of symptomatic 
COPD is associated with a substantial economic burden, especially in the developed 
nations of Europe and North America.
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objeCtives: Chronic Obstructive Pulmonary Disease (COPD) is a main worldwide 
cause of morbidity and mortality. COPD elderly patients spend a large amount of 
money; elderly population is rapidly increasing due to population aging. COPD preva-
lence in 40 years or older people is 7.8% in Mexico City. However, there is no infor-
mation about out-out-pocket expenses of COPD patients in Mexico. Te objective is 
to estimate direct costs of COPD from patient perspective in a third level hospital 
in Mexico. Methods: A pool was developed from august to november of 2013 in a 
third level hospital. We included outpatients and inpatients that had been already 
diagnosed and newly diagnosed with COPD. The diagnosis was carried out by a pul-
monologist according to GOLD criteria. We collected information about direct and 
indirect costs of the patients and the hospital. We estimate median (p25, p75) annual 
cost of medical consultation, clinical test, travel, gasoline and food from outpatients 
and stratifying by severity. All cost were transformed in US Dollars of 2103. Results: 
We interviewed 242 outpatients. According GOLD criteria the patients were classified 
as: mild (n= 18), moderate (n= 105), severe (n= 80) and very severe (n= 39). Median of age 
was 71.7 years, 141 (58.3%) were men and 133 (54.9%) had social security. Annual total 
costs for mild, moderate, severe and very severe were $64.5, $99.9, $130.7 and $138.4, 
respectively. Median costs from mild to very severe were: medical consultation ($23.1, 
$27.7); Clinical test ($11.6, $48.4); travel ($2.2, $33.8); gasoline ($6.9, $13.9) and food ($0, 
18.4). ConClusions: According to total cost, severity is positively correlated with 
the amount of out-of-pocket expenses. The main sources of expenses were medical 
consultations and clinical test.
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objeCtives: Nowadays, health care costs of asthma are under pressure in all coun-
tries due to high prevalence, incidence and the chronic nature of disease. Therefore, 
conducting cost analysis of economic burden of asthma is necessary, especially in 
Vietnam. This is also the aim of this study. Methods: The average cost of asthma 
has been evaluated using pharmacoeconomic method “cost of illness” by following 
formula: COI = DC + IC in which: COI - cost of illness, DC- direct cost, IC- indirect cost 
A tree-decision model has been developed to evaluate the cost of asthma by differ-
ent classification of the severity of asthma. Based on the perspective of insurance 
companies only direct medical costs were evaluated in this study. List of medical ser-
vices and drugs were derived from Guidelines for the diagnosis and management of 
asthma in Vietnam. The price of drugs and medical services have been averaged from 
the price-list of some major hospitals in Vietnam. The cost of disease for the whole 
society of Vietnam has been evaluated based on the cost of disease and the number 
of patients in Vietnam in 2013. Results: The average direct medical cost of asthma 
has increased by the increasing of asthma severity with 3,410,278; 6,548,156; 8,829,234; 
10,746,280 VND in the intermittent, mild, moderate and severe rate of disease severity. 
In the structure of direct cost, with the increasing of asthma severity the percentage of 
costs for drugs increases and the one for medical services reduces. The average direct 
cost of asthma for the whole society of Vietnam resulted in nearly 16,585 billion VND 
per year. ConClusions: The cost of asthma management increases following the 
increasing of disease severity. The high economic burden of asthma (16,585 billion 
VND) should be considered to conduct the relevant health care policies.
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objeCtives: To assess the economic burden and health care utilizations of asthma 
patients in the U.S. Medicare population. Methods: A retrospective analysis was 
conducted using national Medicare data (01JAN2008-31DEC2010). All Medicare bene-
ficiaries diagnosed with asthma were identified using International Classification of 
